It is being evaluated in a phase 2 study for efficacy and safety as monotherapy in patients with metastatic/locally advanced triple-negative, BRCA-mutated breast cancer or just HER2-negative BRCA-mutated breast cancer [62]. The gene discussed is ERBB2; the disease is breast cancer.